Nonmelanoma Skin Cancer – A Comprehensive Medical Guide
Overview
Nonmelanoma skin cancer (NMSC) is a group of skin cancers that arise from cells other than melanocytes, the pigment‑producing cells responsible for melanoma. The two most common types are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Together they account for more than 90 % of all skin cancers.
- Who it affects: Almost anyone can develop NMSC, but it is most frequent in fair‑skinned individuals, men, and people over 50 years of age.
- Prevalence: In the United States, an estimated 5.4 million cases of BCC and 1.1 million cases of SCC are diagnosed each year, making NMSC the most common cancer overall. Worldwide incidence continues to rise with increasing ultraviolet (UV) exposure and aging populations (CDC, 2023; WHO, 2022).
Symptoms
Symptoms vary by cancer type and location, but the following list includes the most frequently reported findings. Any new, changing, or non‑healing skin lesion should be evaluated.
Basal Cell Carcinoma (BCC)
- Pearly or waxy nodule: Often pink, flesh‑colored, or slightly translucent with a rolled border.
- Ulcerated lesion: Central crust or sore that may bleed.
- Telangiectasia: Small, visible blood vessels on the surface of the lesion.
- Scar‑like (sclerodermiform) plaque: Flat, firm area that resembles a scar, especially on the face.
Squamous Cell Carcinoma (SCC)
- Scaly or crusty patch: Often red and rough to the touch.
- Elevated, firm nodule: May ulcerate or bleed.
- Actinic keratosis transformation: A pre‑cancerous, rough, sandpaper‑like spot that suddenly enlarges or becomes painful.
- Non‑healing ulcer: A sore that persists for weeks despite proper wound care.
Symptoms Common to Both Types
- Itching, tenderness, or pain in the lesion.
- Bleeding or oozing with minimal trauma.
- Rapid growth or change in colour, shape, or size.
- Skin that appears “shiny” or “pearly” (more typical of BCC).
Causes and Risk Factors
Nonmelanoma skin cancers are primarily driven by DNA damage from ultraviolet (UV) radiation, but several other factors modify risk.
Primary Causes
- Ultraviolet‑A (UVA) and UV‑B exposure: Cumulative sun exposure damages keratinocytes, leading to mutations in tumor suppressor genes (e.g., PTCH1 for BCC, TP53 for SCC).
- Artificial UV sources: Tanning beds emit high‑intensity UVA/UVB and increase risk, particularly in people who start tanning before age 35.
Risk Factors
- Fair skin, light hair, blue or green eyes, and a propensity to burn rather than tan.
- Age > 50 years (risk rises sharply after 60).
- Male gender (higher incidence, possibly due to occupational sun exposure).
- Personal or family history of skin cancer.
- Chronic immunosuppression (organ transplant recipients, HIV infection, long‑term corticosteroid therapy).
- Exposure to certain chemicals (arsenic, coal tar, industrial solvents) or radiation therapy.
- Presence of numerous actinic keratoses or chronic inflammatory skin conditions (e.g., lupus erythematosus, ulcerated wounds).
Diagnosis
Early detection improves outcomes and often allows for less invasive treatment.
Clinical Examination
- Visual inspection: Dermatologists use a dermatoscope to examine pigment, vascular patterns, and lesion borders.
- Full‑body skin check: Recommended annually for high‑risk individuals.
Biopsy Techniques
- Punch biopsy: A 2–4 mm circular blade removes a full‑thickness sample.
- Excisional biopsy: The entire lesion is removed; preferred for small, well‑defined tumors.
- Shave biopsy: Superficial removal; useful for raised lesions but may miss deeper invasion.
Pathology confirms the diagnosis and determines the cancer’s depth, margins, and histologic subtype.
Additional Tests (when indicated)
- Imaging: Ultrasound, CT, or MRI may be ordered if there is suspicion of deep tissue involvement or metastasis (rare for NMSC).
- Sentinel lymph node biopsy: Considered for high‑risk SCC (large, poorly differentiated, or perineural invasion).
Treatment Options
Treatment choice depends on tumor size, location, histologic type, patient age, and comorbidities.
Procedural Options
- Standard surgical excision: Removal with a 4–6 mm margin for low‑risk lesions; provides cure rates > 95 %.
- Mohs micrographic surgery: Layer‑by‑layer removal with immediate microscopic examination; gold standard for high‑risk or cosmetically sensitive areas (nose, eyelids, ears).
- Curettage and electrodesiccation (C&E): Scraping the tumor followed by cautery; suitable for small, low‑risk BCCs.
- Topical therapies:
- 5‑Fluorouracil (5‑FU) – applied twice daily for 3–4 weeks (effective for superficial BCC and actinic keratoses).
- Imiquimod – immune response modifier, used 5 times per week for 6 weeks (superficial BCC).
- Photodynamic therapy (PDT): Application of a photosensitizing cream (e.g., aminolevulinic acid) followed by red‑light activation; excellent cosmetic results for superficial lesions.
- Radiation therapy: Considered when surgery is contraindicated (e.g., in elderly patients or when lesion is in a difficult location).
- Systemic therapies (advanced cases):
- Hedgehog pathway inhibitors (vismodegib, sonidegib) for metastatic or locally advanced BCC.
- Immune checkpoint inhibitors (cemiplimab) for high‑risk SCC not amenable to surgery or radiation.
Lifestyle and Supportive Measures
- Smoking cessation – improves wound healing and reduces SCC risk.
- Regular skin self‑exams – helps detect new lesions early.
- Multidisciplinary care – dermatology, surgery, oncology, and primary care coordination improves outcomes.
Living with Nonmelanoma Skin Cancer
After treatment, most patients return to normal activities, but ongoing vigilance is essential.
- Sun protection daily: Wear broad‑spectrum SPF 30+ sunscreen, reapply every 2 hours outdoors.
- Skin self‑examination: Conduct a head‑to‑toe check every month; use a mirror for hard‑to‑see areas.
- Follow‑up schedule: Usually every 6–12 months for the first 2 years, then annually, or as advised by your dermatologist.
- Scar management: Use silicone gel sheets or pressure therapy if surgery leaves prominent scars.
- Emotional health: Anxiety about recurrence is common; consider counseling or support groups.
Prevention
Because UV exposure is the leading preventable cause, most preventive strategies focus on protection from the sun.
- UV avoidance: Seek shade between 10 am–4 pm, when UV radiation peaks.
- Protective clothing: Long‑sleeved shirts, wide‑brimmed hats, and UV‑blocking sunglasses.
- Sunscreen use: Apply ¼ teaspoon to each arm, leg, and the front and back of the torso; ½ teaspoon for the face and neck. Choose “broad‑spectrum” formulas.
- Regular skin checks by a professional: At least once a year for average‑risk adults; more often for high‑risk groups.
- Avoid tanning beds: The WHO classifies indoor tanning as a Group 1 carcinogen.
- Vitamin D balance: Obtain vitamin D through diet or supplements rather than intentional UV exposure.
Complications
If left untreated or inadequately treated, NMSC can lead to serious problems.
- Local tissue destruction: SCC can erode into muscle, bone, or cartilage, causing functional impairment (e.g., difficulty swallowing when on the lip or neck).
- Metastasis: Rare for BCC (<0.1 %); SCC metastasizes in 2–5 % of cases, most commonly to regional lymph nodes, lungs, or brain.
- Disfigurement: Large or recurrent tumors may require extensive reconstruction.
- Second primary skin cancers: Patients with a history of NMSC have a 5‑fold increased risk of developing another skin cancer.
- Psychological impact: Chronic treatment and cosmetic concerns can affect quality of life.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you notice any of the following:
- Sudden, uncontrolled bleeding from a skin lesion.
- Severe pain that rapidly worsens.
- Rapid swelling, redness, or warmth suggesting infection (cellulitis) around a tumor.
- Difficulty breathing or swallowing due to a lesion on the face, neck, or throat.
- Signs of systemic illness such as fever, chills, or unexplained weight loss combined with a skin tumor.
Always consult your primary care provider or dermatologist if you notice any new or changing skin lesions, even when symptoms are mild. Early evaluation is the most effective way to prevent complications.
References:
- Centers for Disease Control and Prevention (CDC). “Skin Cancer Statistics.” 2023.
- World Health Organization (WHO). “Ultraviolet Radiation and the Skin.” 2022.
- Mayo Clinic. “Basal cell carcinoma.” Updated 2024.
- Cleveland Clinic. “Squamous cell skin cancer.” 2024.
- National Cancer Institute. “Non‑melanoma skin cancer treatment (PDQ®)–Health Professional Version.” 2023.
- American Academy of Dermatology. “Guidelines of care for the management of basal and squamous cell skin cancer.” 2023.